Cai, Lin
Li, Linfeng
Cheng, Hao
Ding, Yangfeng
Biao, Zhenshu
Zhang, Shifa
Geng, Songmei
Liu, Quanzhong
Fang, Hong
Song, Zhiqi
Lu, Yan
Li, Shanshan
Guo, Qing
Tao, Juan
He, Li
Gu, Jun
Yang, Qinping
Han, Xiuping
Gao, Xinghua
Deng, Danqi
Li, Shenqiu
Wang, Qingyu
Zhu, Jun
Zhang, Jianzhong
Clinical trials referenced in this document:
Documents that mention this clinical trial
FRI0086 CHINA-MANUFACTURED ADALIMUMAB BIOSIMILAR, HLX03, DEMONSTRATED PHARMACOKINETIC EQUIVALENCE AND COMPARABLE SAFETY TO REFERENCE ADALIMUMAB
https://doi.org/10.1136/annrheumdis-2019-eular.1909
Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
https://doi.org/10.1007/s12325-021-01899-0
Funding for this research was provided by:
Shanghai Henlius Biotech, Inc.
Article History
Received: 15 July 2021
Accepted: 19 August 2021
First Online: 23 November 2021